Presenting Lys Therapeutics' groundbreaking mechanism of action of their main drug - a first-in-class monoclonal antibody - Glunozumab to pharma companies and potential investors in a clear, accurate and highly compelling way,
Keywords: 3D, Video, Voiceovers/Narration, Multimedia, Biotechnology, General Medicine, Neuroscience, Neurosurgery, Pharmacology, Mechanism of Action (MOA)